Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free TCRT Stock Alerts

Alaunos Therapeutics (TCRT) Financials

Alaunos Therapeutics logo
$2.07 -0.06 (-2.82%)
Closing price 07/16/2026 04:00 PM Eastern
Extended Trading
$2.12 +0.05 (+2.17%)
As of 07/16/2026 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Alaunos Therapeutics

Annual Income Statements for Alaunos Therapeutics

This table shows Alaunos Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -120 -172 -73 137 -118 -80 -79 -38 -35 -4.68 -4.18
Consolidated Net Income / (Loss)		 -120 -165 -54 -53 -118 -80 -79 -38 -35 -4.68 -4.18
Net Income / (Loss) Continuing Operations		 -120 -165 -54 -53 -118 -80 -79 -38 -35 -4.68 -4.15
Total Pre-Tax Income 		-120 -165 -55 -53 -118 -80 -79 -38 -35 -4.68 -4.15
Total Operating Income		 -120 -165 -53 -54 -58 -80 -78 -35 -34 -4.81 -4.23
Total Gross Profit		 4.33 6.86 6.39 0.15 0.00 0.00 0.40 2.92 0.01 0.01 0.01
Total Revenue		 4.33 6.86 6.39 0.15 0.00 0.00 0.40 2.92 0.01 0.01 0.01
Operating Revenue		 4.33 6.86 6.39 0.15 0.00 0.00 0.40 2.92 0.01 0.01 0.01
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 124 172 60 54 58 80 77 38 34 4.82 4.23
Selling, General & Admin Expense		 18 14 15 20 20 28 28 13 12 4.46 2.87
Research & Development Expense		 107 158 45 34 38 53 50 25 16 0.36 1.36
Total Other Income / (Expense), net		 0.00 -0.12 -1.30 0.79 -60 0.00 -1.20 -2.63 -0.87 0.13 0.05
Other Income / (Expense), net		 - -0.12 -1.30 0.79 -60 - -0.01 0.53 1.05 0.13 0.08
Basic Earnings per Share		 ($0.96) ($1.32) ($0.53) $0.96 ($0.70) $0.00 ($0.37) ($2.61) ($21.97) ($2.92) ($2.20)
Weighted Average Basic Shares Outstanding		 125.42M 130.39M 136.94M 143.51M 167.95M 209.64M 214.40M 14.48M 1.60M 1.60M 1.95M
Diluted Earnings per Share		 ($0.96) ($1.32) ($0.53) $0.96 ($0.70) $0.00 ($0.37) ($2.61) ($21.97) ($2.92) ($2.20)
Weighted Average Diluted Shares Outstanding		 125.42M 130.39M 136.94M 143.71M 167.95M 0.00 214.40M 14.48M 1.60M 1.60M 1.95M
Weighted Average Basic & Diluted Shares Outstanding		 125.42M 130.39M 138.20M 138.60M 213.00M 214.67M 216.13M 240.63M 16.01M 1.60M 2.38M

Quarterly Income Statements for Alaunos Therapeutics

This table shows Alaunos Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -8.48 -7.84 -1.68 -1.13 -1.13 -0.74 -1.07 0.00 -1.16 -1.94 -1.01
Consolidated Net Income / (Loss)		 -8.48 -7.84 -1.68 -1.13 -1.13 -0.74 -1.07 -1.05 -1.16 -0.89 -1.01
Net Income / (Loss) Continuing Operations		 -8.48 -7.84 -1.68 -1.13 -1.13 -0.74 -1.07 -1.05 -1.16 -0.86 -1.01
Total Pre-Tax Income 		-8.48 -7.84 -1.68 -1.13 -1.13 -0.74 -1.07 -1.05 -1.16 -0.86 -1.01
Total Operating Income		 -8.66 -7.95 -1.74 -1.17 -1.15 -0.75 -1.09 -1.04 -1.19 -0.91 -1.01
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 8.66 7.95 1.74 1.17 1.15 0.76 1.09 1.04 1.19 0.91 1.01
Selling, General & Admin Expense		 3.58 2.43 1.62 0.99 1.01 0.85 0.75 0.85 0.72 0.55 0.59
Research & Development Expense		 3.66 0.93 0.13 0.18 0.14 -0.09 0.35 0.19 0.47 0.36 0.43
Total Other Income / (Expense), net		 0.19 0.11 0.06 0.04 0.02 0.01 0.02 -0.01 0.03 0.01 0.01
Other Income / (Expense), net		 0.19 0.11 0.06 0.04 0.02 0.01 0.02 -0.01 0.03 0.05 0.01
Basic Earnings per Share		 ($5.30) ($4.90) ($1.05) ($0.71) ($0.70) ($0.46) ($0.67) ($0.63) ($0.55) ($1.00) ($0.59)
Weighted Average Basic Shares Outstanding		 1.60M 1.60M 1.60M 1.60M 1.60M 1.60M 1.60M 1.68M 2.18M 1.95M 1.95M
Diluted Earnings per Share		 ($5.30) ($4.90) ($1.05) ($0.71) ($0.70) ($0.46) ($0.67) ($0.63) ($0.55) ($1.00) ($0.59)
Weighted Average Diluted Shares Outstanding		 1.60M 1.60M 1.60M 1.60M 1.60M 1.60M 1.60M 1.68M 2.18M 1.95M 1.95M
Weighted Average Basic & Diluted Shares Outstanding		 240.63M 16.01M 16.01M 1.60M 1.60M 1.60M 1.64M 2.19M 2.23M 2.38M 24.42M

Annual Cash Flow Statements for Alaunos Therapeutics

This table details how cash moves in and out of Alaunos Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 98 -60 -10 -9.61 18 12 -39 -23 -47 -4.97 0.29
Net Cash From Operating Activities		 -0.01 -58 -55 -49 -41 -57 -61 -29 -30 -4.97 -2.87
Net Cash From Continuing Operating Activities		 -0.01 -58 -55 -49 -41 -80 -61 -29 -30 -4.97 -2.87
Net Income / (Loss) Continuing Operations		 -120 -165 -54 -53 -118 -80 -79 -38 -35 -4.68 -4.18
Consolidated Net Income / (Loss)		 -120 -165 -54 -53 -118 -80 -79 -38 -35 -4.68 -4.18
Depreciation Expense		 0.36 0.29 0.37 0.58 0.63 1.13 2.60 2.76 2.32 0.00 0.01
Non-Cash Adjustments To Reconcile Net Income		 75 128 9.75 7.38 68 4.45 12 3.89 7.64 0.44 0.83
Changes in Operating Assets and Liabilities, net		 44 -21 -10 -4.29 8.22 17 2.79 0.87 -6.30 -0.73 0.47
Net Cash From Investing Activities		 -0.41 -0.55 -0.74 -0.46 -0.28 -9.78 -3.32 -0.19 1.35 0.00 -0.10
Net Cash From Continuing Investing Activities		 -0.41 -0.55 -0.74 -0.46 -0.28 -9.78 -3.32 -0.19 1.35 0.00 -0.10
Purchase of Property, Plant & Equipment		 -0.41 -0.55 -0.74 -0.46 -0.28 -9.78 -3.32 -0.22 -0.20 0.00 -0.10
Net Cash From Financing Activities		 98 -0.79 45 40 59 102 26 6.37 -18 0.00 3.26
Net Cash From Continuing Financing Activities		 98 -0.79 45 40 59 102 26 6.37 -18 0.00 3.26
Repurchase of Preferred Equity		 - - - - - - - - - 0.00 1.35
Issuance of Common Equity		 94 - 47 0.00 6.09 13 0.00 15 0.09 0.00 1.91
Cash Interest Paid		 0.00 0.00 - - - 0.00 0.63 2.17 2.06 0.00 0.00

Quarterly Cash Flow Statements for Alaunos Therapeutics

This table details how cash moves in and out of Alaunos Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -6.37 -5.88 -1.92 -1.68 -0.78 -0.59 -0.77 2.56 -0.94 -0.55 -1.03
Net Cash From Operating Activities		 -6.37 -7.39 -1.92 -1.68 -0.78 -0.59 -0.77 -0.70 -0.84 -0.55 -1.03
Net Cash From Continuing Operating Activities		 -6.37 -7.39 -1.92 -1.68 -0.78 -0.59 -0.77 -0.70 -0.84 -0.55 -1.03
Net Income / (Loss) Continuing Operations		 -8.48 -7.84 -1.68 -1.13 -1.13 -0.74 -1.07 -1.05 -1.16 -0.89 -1.01
Consolidated Net Income / (Loss)		 -8.48 -7.84 -1.68 -1.13 -1.13 -0.74 -1.07 -1.05 -1.16 -0.89 -1.01
Depreciation Expense		 0.68 0.24 - - - -0.00 0.00 - - 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 3.07 2.98 0.17 0.10 0.08 0.08 0.07 0.22 0.30 0.24 0.14
Changes in Operating Assets and Liabilities, net		 -1.65 -2.76 -0.41 -0.66 0.27 0.07 0.23 0.14 0.01 0.09 -0.17
Net Cash From Investing Activities		 0.00 1.50 0.00 - - - 0.00 - -0.10 -0.00 0.00
Net Cash From Continuing Investing Activities		 0.00 1.50 0.00 - - - 0.00 - -0.10 -0.00 0.00
Net Cash From Financing Activities		 - - 0.00 - - - 0.00 3.26 - - 0.00
Net Cash From Continuing Financing Activities		 - - 0.00 - - - 0.00 3.26 - - 0.00

Annual Balance Sheets for Alaunos Therapeutics

This table presents Alaunos Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 154 106 106 95 109 146 95 65 8.26 2.76 2.97
Total Current Assets		 153 105 91 84 105 131 79 54 8.26 2.76 1.99
Cash & Equivalents		 141 81 71 62 80 115 76 39 6.06 1.09 1.39
Accounts Receivable		 0.45 0.02 0.02 1.86 3.33 4.67 1.11 0.00 0.00 0.01 0.00
Prepaid Expenses		 11 24 20 21 22 11 1.67 0.80 2.20 1.66 0.60
Plant, Property, & Equipment, net		 0.58 0.84 1.21 1.10 1.11 10 11 8.46 0.00 0.00 0.09
Total Noncurrent Assets		 0.62 0.62 14 9.67 2.51 5.53 5.09 2.68 0.00 0.00 0.89
Other Noncurrent Operating Assets		 0.62 0.62 14 9.67 2.51 5.53 5.09 2.68 0.00 0.00 0.89
Total Liabilities & Shareholders' Equity		 154 106 106 95 109 146 95 65 8.26 2.76 2.97
Total Liabilities		 66 58 58 9.49 14 22 37 26 1.96 0.69 0.81
Total Current Liabilities		 18 16 21 9.48 13 18 16 24 1.96 0.69 0.81
Accounts Payable		 2.01 0.16 4.42 0.71 0.91 0.96 1.37 1.39 0.62 0.52 0.61
Accrued Expenses		 8.91 9.11 9.91 8.76 11 17 6.08 5.45 1.34 0.18 0.20
Total Noncurrent Liabilities		 48 43 38 0.00 1.58 4.00 21 2.22 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 87 -77 -97 86 95 124 58 39 6.31 2.06 2.15
Total Preferred & Common Equity		 87 -77 -97 86 95 124 58 39 6.31 2.06 2.15
Preferred Stock		 - 0.00 0.00 - 0.00 - - - - 0.00 0.00
Total Common Equity		 87 -77 -97 86 95 124 58 39 6.31 2.06 2.15
Common Stock		 580 581 616 652 779 888 901 919 922 923 927
Retained Earnings		 -493 -658 -712 -566 -684 -764 -843 -881 -916 -920 -925

Quarterly Balance Sheets for Alaunos Therapeutics

This table presents Alaunos Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 19 6.04 4.68 3.55 2.12 4.74 3.72 1.88
Total Current Assets		 13 6.04 4.68 3.55 1.07 3.74 2.69 0.97
Cash & Equivalents		 12 4.15 2.46 1.68 0.32 2.88 1.94 0.35
Accounts Receivable		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Prepaid Expenses		 0.93 1.89 2.21 1.87 0.75 0.86 0.75 0.62
Plant, Property, & Equipment, net		 5.53 0.00 0.00 0.00 0.00 0.00 0.10 0.08
Total Noncurrent Assets		 1.04 0.00 0.00 0.00 1.05 1.00 0.94 0.83
Other Noncurrent Operating Assets		 1.04 - - - 1.05 1.00 0.94 0.83
Total Liabilities & Shareholders' Equity		 19 6.04 4.68 3.55 2.12 4.74 3.72 1.88
Total Liabilities		 5.54 1.24 0.91 0.83 1.06 1.07 0.92 0.60
Total Current Liabilities		 4.68 1.24 0.91 0.83 1.06 1.07 0.92 0.60
Accounts Payable		 1.30 0.60 0.37 0.46 0.83 0.81 0.84 0.40
Accrued Expenses		 3.07 0.64 0.54 0.37 0.23 0.27 0.08 0.20
Total Noncurrent Liabilities		 0.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 14 4.80 3.77 2.72 1.06 3.66 2.80 1.29
Total Preferred & Common Equity		 14 4.80 3.77 2.72 1.06 3.66 2.80 1.29
Preferred Stock		 - - - - - 0.00 0.00 0.00
Total Common Equity		 14 4.80 3.77 2.72 1.06 3.66 2.80 1.29
Common Stock		 922 922 922 922 923 926 927 927
Retained Earnings		 -908 -917 -919 -920 -922 -923 -924 -926

Annual Metrics And Ratios for Alaunos Therapeutics

This table displays calculated financial ratios and metrics derived from Alaunos Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 130,888,901.00 131,732,423.00 141,962,789.00 142,379,770.00 181,030,020.00 214,291,057.00 216,145,826.00 216,182,042.00 240,627,055.00 1,601,252.00 2,231,829.00
DEI Adjusted Shares Outstanding		 872,593.00 878,216.00 946,419.00 949,198.00 1,206,867.00 1,428,607.00 1,440,972.00 1,441,214.00 1,604,180.00 1,601,252.00 2,231,829.00
DEI Earnings Per Adjusted Shares Outstanding		 -137.62 -196.33 -77.41 144.59 -97.60 -55.98 -54.65 -26.18 -21.91 -2.92 -1.87
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 215.51% 58.38% -6.88% -97.71% -100.00% 0.00% 0.00% 634.17% -99.83% 100.00% -50.00%
EBITDA Growth		 -282.39% -37.91% 67.05% 3.45% -123.00% 32.38% 5.87% 58.65% 4.12% 84.18% 11.52%
EBIT Growth		 -277.96% -37.74% 66.88% 3.05% -121.77% 31.78% 3.48% 55.42% 3.92% 85.91% 11.41%
NOPAT Growth		 -176.10% -37.64% 67.64% -0.77% -7.33% -38.89% 3.50% 54.73% 2.39% 85.96% 12.20%
Net Income Growth		 -277.86% -37.65% 67.14% 2.22% -121.77% 32.11% 1.53% 52.09% 6.86% 86.68% 10.75%
EPS Growth		 -209.68% -37.50% 59.85% 281.13% -172.92% 100.00% 0.00% 52.09% 6.86% 86.71% 24.66%
Operating Cash Flow Growth		 99.97% -583,150.00% 6.27% 9.53% 17.39% -39.55% -7.81% 52.44% -3.11% 83.51% 42.29%
Free Cash Flow Firm Growth		 1.54% -242.77% 65.66% -82.66% 62.57% -56.25% -3.20% 59.65% -5.44% 81.31% 32.77%
Invested Capital Growth		 -495.25% 38.08% 28.07% 200.32% -35.94% -41.63% -31.34% -62.03% -89.46% 296.73% -20.99%
Revenue Q/Q Growth		 57.36% -4.48% 0.00% -93.77% 100.00% 0.00% 0.00% 0.38% -66.67% 66.67% -28.57%
EBITDA Q/Q Growth		 0.87% -1.07% -7.03% -7.63% -99.13% -8.93% 14.09% 8.54% -1.28% 59.46% -2.81%
EBIT Q/Q Growth		 0.92% -1.07% -7.07% -7.66% -98.13% -9.15% 13.12% 7.44% 1.27% 60.28% -3.01%
NOPAT Q/Q Growth		 0.92% -1.00% -4.54% -8.44% 2.69% -9.15% 13.13% 6.72% 1.65% 59.92% -3.76%
Net Income Q/Q Growth		 0.76% -1.07% -3.92% -8.35% 1.36% -9.63% 12.23% 6.53% 3.61% 60.28% -3.78%
EPS Q/Q Growth		 6.80% -7.32% -1.92% 0.00% 0.00% 100.00% 11.90% 6.53% 3.61% 60.33% -61.76%
Operating Cash Flow Q/Q Growth		 -100.07% 15.55% 1.63% 0.68% 0.51% -10.52% 3.01% 21.48% -0.85% 57.74% 1.38%
Free Cash Flow Firm Q/Q Growth		 -62.03% 7.64% 2.61% -164.84% 63.44% -16.15% 5.06% 26.28% 6.01% 45.32% -2.96%
Invested Capital Q/Q Growth		 23.79% 11.42% 5.47% 186.01% -15.29% -5.65% 412.99% -23.45% -87.47% -6.63% -11.21%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,764.15% -2,406.95% -851.76% -35,987.67% 0.00% 0.00% -18,739.20% -1,055.30% -591,300.00% -46,770.00% -82,760.00%
Operating Margin		 -2,772.39% -2,409.37% -837.27% -36,921.92% 0.00% 0.00% -19,484.67% -1,201.40% -685,340.00% -48,120.00% -84,500.00%
EBIT Margin		 -2,772.39% -2,411.18% -857.54% -36,381.51% 0.00% 0.00% -19,487.94% -1,183.30% -664,380.00% -46,790.00% -82,900.00%
Profit (Net Income) Margin		 -2,772.11% -2,409.23% -850.26% -36,381.51% 0.00% 0.00% -19,786.68% -1,291.24% -702,800.00% -46,790.00% -83,520.00%
Tax Burden Percent		 99.99% 99.92% 99.15% 100.00% 100.00% 99.52% 100.00% 100.00% 100.00% 100.00% 100.75%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 101.53% 109.12% 105.78% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -100,624.53% 0.00% 0.00% -722.20% -582.03% -1,867.41% -553.56% -339.94%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -100,601.34% 0.00% 0.00% -692.90% -552.19% -1,814.67% -516.91% -241.52%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 100,544.51% 0.00% 0.00% 635.68% 503.93% 1,710.75% 441.75% 141.84%
Return on Equity (ROE)		 -198.15% -244.17% -114.11% -80.03% -130.47% -73.04% -86.52% -78.11% -156.66% -111.80% -198.10%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -358.00% -163.33% -412.68% -685.04% -492.12% -1,705.56% -673.03% -316.49%
Operating Return on Assets (OROA)		 -120.73% -127.22% -51.70% -52.94% 0.00% 0.00% -64.31% -43.27% -90.76% -84.93% -144.90%
Return on Assets (ROA)		 -120.72% -127.12% -51.26% -52.94% 0.00% 0.00% -65.30% -47.22% -96.01% -84.93% -145.99%
Return on Common Equity (ROCE)		 -198.15% -18.17% 208.67% 6.78% -130.47% -73.04% -86.52% -78.11% -156.66% -111.80% -198.10%
Return on Equity Simple (ROE_SIMPLE)		 -137.45% 213.84% 56.12% -62.08% -123.98% -64.51% -135.64% -97.86% -557.16% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -84 -116 -37 -38 -41 -56 -54 -25 -24 -3.37 -2.96
NOPAT Margin		 -1,940.67% -1,686.56% -586.09% -25,845.34% 0.00% 0.00% -13,639.27% -840.98% -479,738.00% -33,684.00% -59,150.00%
Net Nonoperating Expense Percent (NNEP)		 -39.25% -44.71% -22.21% -23.19% -109.27% -24.36% -29.30% -29.84% -52.74% -36.64% -98.42%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -380.32% -163.28% -137.37%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 407.36% 209.55% 231.62% 13,642.47% 0.00% 0.00% 6,925.63% 449.76% 244,380.00% 44,600.00% 57,340.00%
R&D to Revenue		 2,465.03% 2,299.83% 705.65% 23,379.45% 0.00% 0.00% 12,473.12% 856.19% 325,580.00% 3,620.00% 27,260.00%
Operating Expenses to Revenue		 2,872.39% 2,509.37% 937.27% 37,021.92% 0.00% 0.00% 19,398.74% 1,301.40% 685,440.00% 48,220.00% 84,600.00%
Earnings before Interest and Taxes (EBIT)		 -120 -165 -55 -53 -118 -80 -78 -35 -33 -4.68 -4.15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -120 -165 -54 -53 -117 -79 -75 -31 -30 -4.68 -4.14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 12.45 0.00 0.00 3.11 8.99 4.36 4.06 3.64 2.70 1.48 3.35
Price to Tangible Book Value (P/TBV)		 12.45 0.00 0.00 3.11 8.99 4.36 4.06 3.64 2.70 1.48 3.35
Price to Revenue (P/Rev)		 251.08 102.72 91.99 1,823.63 0.00 0.00 591.96 48.02 3,402.47 305.04 1,441.76
Price to Earnings (P/E)		 0.00 0.00 0.00 1.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 51.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 8.58 50.74 47.68 30.01 44.79 44.70 2.02 7.58
Enterprise Value to Revenue (EV/Rev)		 218.60 109.17 103.42 1,400.83 0.00 0.00 461.46 35.62 2,190.07 195.94 1,164.76
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.42 0.43 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.28 0.00 0.00 0.00 0.00
Financial Leverage		 -1.51 -1.64 -1.60 -1.00 -0.78 -0.89 -0.92 -0.91 -0.94 -0.85 -0.59
Leverage Ratio		 1.64 1.92 2.23 1.51 1.13 1.17 1.33 1.65 1.63 1.32 1.36
Compound Leverage Factor		 1.64 1.92 2.23 1.51 1.13 1.17 1.35 1.80 1.73 1.32 1.36
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 29.35% 30.31% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.57% 30.31% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 19.77% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 260.96% 305.16% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% -160.96% -205.16% 100.00% 100.00% 100.00% 70.65% 69.69% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.32 -0.54 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.70 1.18 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.22 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.44 -0.68 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.96 1.47 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.30 0.00 0.00 0.00 0.00
Altman Z-Score		 3.85 -5.48 -4.27 7.60 25.03 6.29 -10.50 -16.96 -162.29 -469.80 -435.25
Noncontrolling Interest Sharing Ratio		 0.00% 92.56% 282.87% 108.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.42 6.63 4.35 8.89 8.42 7.11 4.91 2.23 4.22 3.98 2.45
Quick Ratio		 7.79 5.13 3.40 6.71 6.63 6.52 4.81 1.62 3.10 1.58 1.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -40 -136 -47 -85 -32 -50 -51 -21 -22 -4.10 -2.75
Operating Cash Flow to CapEx		 -2.43% -10,585.30% -7,417.77% -10,774.95% -14,385.21% -583.07% -1,849.77% -15,146.11% 0.00% 0.00% -2,927.55%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -43.31 -6.59 -11.40 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -51.70 -9.27 -15.69 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -54.49 -9.33 -14.99 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.04 0.05 0.06 0.00 0.00 0.00 0.00 0.04 0.00 0.00 0.00
Accounts Receivable Turnover		 14.66 29.38 319.45 0.16 0.00 0.00 0.14 5.24 2.00 3.33 1.25
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 7.79 9.64 6.22 0.13 0.00 0.00 0.04 0.30 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 24.90 12.42 1.14 2,353.75 0.00 0.00 2,648.54 69.64 182.50 109.50 292.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 24.90 12.42 1.14 2,353.75 0.00 0.00 2,648.54 69.64 182.50 109.50 292.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -53 -33 -24 24 15 8.91 6.12 2.32 0.25 0.97 0.77
Invested Capital Turnover		 -0.14 -0.16 -0.23 3.89 0.00 0.00 0.05 0.69 0.00 0.02 0.01
Increase / (Decrease) in Invested Capital		 -44 20 9.27 48 -8.57 -6.36 -2.79 -3.80 -2.08 0.73 -0.20
Enterprise Value (EV)		 947 749 661 205 775 425 184 104 11 1.96 5.82
Market Capitalization		 1,088 705 588 266 854 540 236 140 17 3.05 7.21
Book Value per Share		 $0.67 ($0.59) ($0.68) $0.60 $0.52 $0.58 $0.27 $0.18 $0.03 $1.29 $0.96
Tangible Book Value per Share		 $0.67 ($0.59) ($0.68) $0.60 $0.52 $0.58 $0.27 $0.18 $0.03 $1.29 $0.96
Total Capital		 87 48 47 86 95 124 82 55 6.31 2.06 2.15
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 24 17 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 16 0.00 0.00 0.00 0.00
Net Debt		 -141 -81 -71 -62 -80 -115 -52 -36 -6.06 -1.09 -1.39
Capital Expenditures (CapEx)		 0.41 0.55 0.74 0.46 0.28 9.78 3.32 0.19 -1.35 0.00 0.10
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.32 8.02 -1.02 13 13 -2.85 -5.40 -6.60 0.24 0.97 -0.21
Debt-free Net Working Capital (DFNWC)		 134 89 70 75 93 112 71 46 6.31 2.06 1.18
Net Working Capital (NWC)		 134 89 70 75 93 112 63 30 6.31 2.06 1.18
Net Nonoperating Expense (NNE)		 36 50 17 15 77 24 24 13 11 1.31 1.22
Net Nonoperating Obligations (NNO)		 -141 -81 -71 -62 -80 -115 -52 -36 -6.06 -1.09 -1.39
Total Depreciation and Amortization (D&A)		 0.36 0.29 0.37 0.58 0.63 1.13 2.98 3.74 3.65 0.00 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -145.87% 116.92% -15.95% 8,954.11% 0.00% 0.00% -1,355.78% -225.80% 4,860.00% 9,720.00% -4,200.00%
Debt-free Net Working Capital to Revenue		 3,102.45% 1,298.28% 1,094.49% 51,234.25% 0.00% 0.00% 17,753.27% 1,587.89% 126,100.00% 20,630.00% 23,500.00%
Net Working Capital to Revenue		 3,102.45% 1,298.28% 1,094.49% 51,234.25% 0.00% 0.00% 15,776.38% 1,014.13% 126,100.00% 20,630.00% 23,500.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($144.00) ($198.00) ($79.50) $144.00 ($105.00) ($57.00) $0.00 ($25.50) ($22.00) ($2.92) ($2.20)
Adjusted Weighted Average Basic Shares Outstanding		 878.12K 882.51K 949.33K 956.72K 1.12M 1.40M 1.43M 1.45M 1.60M 1.60M 1.95M
Adjusted Diluted Earnings per Share		 ($144.00) ($198.00) ($79.50) $144.00 ($105.00) ($57.00) $0.00 ($25.50) ($22.00) ($2.92) ($2.20)
Adjusted Weighted Average Diluted Shares Outstanding		 878.12K 882.51K 949.33K 958.07K 1.12M 1.40M 0.00 1.45M 1.60M 1.60M 1.95M
Adjusted Basic & Diluted Earnings per Share		 ($144.00) ($198.00) ($79.50) $0.00 $0.00 $0.00 ($55.50) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 836.11K 869.28K 912.92K 1.08M 1.42M 1.43M 1.44M 1.60M 1.60M 1.60M 2.38M
Normalized Net Operating Profit after Tax (NOPAT)		 -84 -116 -37 -38 -41 -56 -54 -25 -20 -3.37 -2.96
Normalized NOPAT Margin		 -1,940.67% -1,686.56% -586.09% -25,845.34% 0.00% 0.00% -13,509.12% -840.98% -394,730.00% -33,684.00% -59,150.00%
Pre Tax Income Margin		 -2,772.39% -2,411.18% -857.54% -36,381.51% 0.00% 0.00% -19,786.68% -1,291.24% -702,800.00% -46,790.00% -82,900.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -65.23 -10.96 -17.29 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -45.66 -7.79 -12.49 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -68.03 -11.02 -16.59 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -48.45 -7.85 -11.79 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.46% -0.91% -3.79% -3.05% -0.55% 0.00% 0.00% -0.12% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Alaunos Therapeutics

This table displays calculated financial ratios and metrics derived from Alaunos Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 240,627,055.00 240,627,055.00 16,012,479.00 16,012,522.00 1,601,252.00 1,601,252.00 1,601,252.00 1,639,521.00 2,194,941.00 2,231,829.00 2,378,253.00
DEI Adjusted Shares Outstanding		 1,604,180.00 1,604,180.00 1,601,248.00 1,601,252.00 1,601,252.00 1,601,252.00 1,601,252.00 1,639,521.00 2,194,941.00 2,231,829.00 2,378,253.00
DEI Earnings Per Adjusted Shares Outstanding		 -5.28 -4.89 -1.05 -0.71 -0.70 -0.46 -0.67 0.00 -0.53 -0.87 -0.42
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% -90.91% 0.00% 0.00% 0.00% 400.00% 100.00% -100.00% 0.00% -40.00% -100.00%
EBITDA Growth		 -9.97% -5.17% 79.05% 81.61% 85.55% 90.24% 36.21% 6.91% -2.84% -15.23% 6.99%
EBIT Growth		 -5.82% 5.15% 81.71% 85.35% 86.70% 90.55% 36.21% 6.91% -2.84% -16.33% 6.24%
NOPAT Growth		 -4.84% 6.73% 81.99% 85.39% 86.73% 90.51% 37.31% 10.89% -3.22% -20.29% 7.33%
Net Income Growth		 4.24% 14.37% 83.26% 87.13% 86.70% 90.55% 36.21% 6.91% -2.84% -20.51% 6.24%
EPS Growth		 4.24% 14.37% 83.26% 87.13% 86.79% 90.61% 36.19% 11.27% 21.43% -117.39% 11.94%
Operating Cash Flow Growth		 -3.73% -3.58% 79.57% 75.99% 87.75% 91.98% 59.73% 58.30% -8.07% 6.76% -33.55%
Free Cash Flow Firm Growth		 34.65% -60.61% 125.62% 128.59% 102.21% 64.00% -171.45% -116.65% -695.36% 65.66% -6.11%
Invested Capital Growth		 -35.57% -89.46% -78.71% -60.76% -46.78% 296.73% 13.34% -40.21% -16.91% -20.99% 26.39%
Revenue Q/Q Growth		 -100.00% 0.00% 0.00% 300.00% -100.00% 0.00% -60.00% -100.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 -27.01% 2.50% 77.87% 32.88% 0.18% 34.16% -44.61% 2.05% -10.28% 26.23% -16.73%
EBIT Q/Q Growth		 -10.01% 7.47% 78.55% 32.88% 0.18% 34.25% -44.80% 2.05% -10.28% 25.63% -16.71%
NOPAT Q/Q Growth		 -8.54% 8.25% 78.09% 33.07% 1.37% 34.43% -44.83% 4.85% -14.24% 23.59% -11.58%
Net Income Q/Q Growth		 3.39% 7.47% 78.55% 32.88% 0.18% 34.25% -44.80% 2.05% -10.28% 22.95% -12.65%
EPS Q/Q Growth		 3.39% 7.47% 78.55% 32.88% 1.41% 34.29% -45.65% 5.97% 12.70% -81.82% 41.00%
Operating Cash Flow Q/Q Growth		 8.97% -15.86% 74.04% 12.31% 53.54% 24.20% -30.41% 9.20% -20.40% 34.60% -86.78%
Free Cash Flow Firm Q/Q Growth		 -17.89% 30.08% 134.19% 1.44% -90.90% -1,240.73% 32.15% 76.36% -225.34% 34.20% -109.65%
Invested Capital Q/Q Growth		 -41.31% -87.47% 166.12% 100.61% -20.41% -6.63% -23.97% 5.82% 10.61% -11.21% 21.61%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 0.00% -760,200.00% -168,200.00% -28,225.00% 0.00% -14,840.00% -53,650.00% 0.00% 0.00% -28,500.00% 0.00%
Operating Margin		 0.00% -794,900.00% -174,200.00% -29,150.00% 0.00% -15,080.00% -54,600.00% 0.00% 0.00% -30,233.33% 0.00%
EBIT Margin		 0.00% -784,300.00% -168,200.00% -28,225.00% 0.00% -14,820.00% -53,650.00% 0.00% 0.00% -28,733.33% 0.00%
Profit (Net Income) Margin		 0.00% -784,300.00% -168,200.00% -28,225.00% 0.00% -14,820.00% -53,650.00% 0.00% 0.00% -29,766.67% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 103.60% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -2,165.94% -393.88% -52.76% 0.00% -173.48% -604.49% 0.00% 0.00% -121.63% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -2,155.16% -390.86% -49.75% 0.00% -167.51% -590.66% 0.00% 0.00% -100.78% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 2,031.75% 348.53% 40.67% 0.00% 143.16% 450.33% 0.00% 0.00% 59.19% 0.00%
Return on Equity (ROE)		 0.00% -134.19% -45.35% -12.09% 0.00% -30.32% -154.15% 0.00% 0.00% -62.44% 0.00%
Cash Return on Invested Capital (CROIC)		 -933.84% -1,705.56% -862.71% -501.60% -499.83% -673.03% -431.40% -219.95% -280.63% -316.49% -370.17%
Operating Return on Assets (OROA)		 0.00% -107.14% -36.92% -10.39% 0.00% -26.90% -144.70% 0.00% 0.00% -50.22% 0.00%
Return on Assets (ROA)		 0.00% -107.14% -36.92% -10.39% 0.00% -26.90% -144.70% 0.00% 0.00% -52.03% 0.00%
Return on Common Equity (ROCE)		 0.00% -134.19% -45.35% -12.09% 0.00% -30.32% -154.15% 0.00% 0.00% -62.44% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -262.27% 0.00% -558.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.06 -5.56 -1.22 -0.82 -0.81 -0.53 -0.76 -0.73 -0.83 -0.63 -0.71
NOPAT Margin		 0.00% -556,430.00% -121,940.00% -20,405.00% 0.00% -10,556.00% -38,220.00% 0.00% 0.00% -21,163.33% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -11.76% -10.78% -3.02% -3.01% -4.73% -5.96% -13.83% -12.12% -18.12% -20.85% -88.44%
Return On Investment Capital (ROIC_SIMPLE)		 - -88.22% -25.42% -21.64% -29.55% -25.58% -72.25% -19.87% -29.64% -29.49% -55.00%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 242,800.00% 161,700.00% 24,750.00% 0.00% 16,920.00% 37,350.00% 0.00% 0.00% 18,266.67% 0.00%
R&D to Revenue		 0.00% 93,300.00% 12,600.00% 4,500.00% 0.00% -1,740.00% 17,350.00% 0.00% 0.00% 12,066.67% 0.00%
Operating Expenses to Revenue		 0.00% 795,000.00% 174,300.00% 29,250.00% 0.00% 15,180.00% 54,700.00% 0.00% 0.00% 30,333.33% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.48 -7.84 -1.68 -1.13 -1.13 -0.74 -1.07 -1.05 -1.16 -0.86 -1.01
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.80 -7.60 -1.68 -1.13 -1.13 -0.74 -1.07 -1.05 -1.16 -0.86 -1.00
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.28 2.70 6.05 2.97 1.89 1.48 2.22 2.17 1.89 3.35 5.28
Price to Tangible Book Value (P/TBV)		 2.28 2.70 6.05 2.97 1.89 1.48 2.22 2.17 1.89 3.35 5.28
Price to Revenue (P/Rev)		 2,114.31 3,402.47 4,839.28 1,865.46 859.34 305.04 213.99 1,135.95 755.69 1,441.76 2,267.27
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 10.11 44.70 38.18 6.67 3.34 2.02 2.75 6.49 3.87 7.58 6.90
Enterprise Value to Revenue (EV/Rev)		 1,318.04 2,190.07 4,148.44 1,454.96 578.84 195.94 184.99 724.67 478.83 1,164.76 2,149.27
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.89 -0.94 -0.89 -0.82 -0.82 -0.85 -0.76 -0.72 -0.66 -0.59 -0.29
Leverage Ratio		 1.89 1.63 1.59 1.28 1.38 1.32 1.39 1.27 1.32 1.36 1.71
Compound Leverage Factor		 1.89 1.63 1.59 1.28 1.38 1.32 1.39 1.27 1.32 1.36 1.71
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -62.88 -152.16 -198.67 -267.33 -359.08 -465.08 -608.88 -268.39 -344.28 -431.60 -682.86
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.75 4.22 4.87 5.16 4.30 3.98 1.00 3.48 2.92 2.45 1.63
Quick Ratio		 2.55 3.10 3.34 2.72 2.04 1.58 0.30 2.68 2.10 1.71 0.60
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.98 -3.49 1.19 1.21 0.11 -1.25 -0.85 -0.20 -0.65 -0.43 -0.90
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -55,200.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 2.00 0.00 1.50 0.00 3.33 7.33 2.33 0.00 1.25 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 182.50 0.00 243.33 0.00 109.50 49.77 156.43 0.00 292.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 182.50 0.00 243.33 0.00 109.50 49.77 156.43 0.00 292.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.96 0.25 0.65 1.31 1.04 0.97 0.74 0.78 0.87 0.77 0.93
Invested Capital Turnover		 0.01 0.00 0.00 0.00 0.00 0.02 0.02 0.01 0.01 0.01 0.00
Increase / (Decrease) in Invested Capital		 -1.08 -2.08 -2.41 -2.03 -0.92 0.73 0.09 -0.53 -0.18 -0.20 0.20
Enterprise Value (EV)		 20 11 25 8.73 3.47 1.96 2.03 5.07 3.35 5.82 6.45
Market Capitalization		 32 17 29 11 5.16 3.05 2.35 7.95 5.29 7.21 6.80
Book Value per Share		 $0.06 $0.03 $0.02 $0.24 $1.70 $1.29 $0.66 $2.23 $1.28 $0.96 $0.58
Tangible Book Value per Share		 $0.06 $0.03 $0.02 $0.24 $1.70 $1.29 $0.66 $2.23 $1.28 $0.96 $0.58
Total Capital		 14 6.31 4.80 3.77 2.72 2.06 1.06 3.66 2.80 2.15 1.29
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -12 -6.06 -4.15 -2.46 -1.68 -1.09 -0.32 -2.88 -1.94 -1.39 -0.35
Capital Expenditures (CapEx)		 -0.00 -1.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.75 0.24 0.65 1.31 1.04 0.97 -0.31 -0.22 -0.17 -0.21 0.02
Debt-free Net Working Capital (DFNWC)		 8.19 6.31 4.80 3.77 2.72 2.06 0.01 2.66 1.76 1.18 0.38
Net Working Capital (NWC)		 8.19 6.31 4.80 3.77 2.72 2.06 0.01 2.66 1.76 1.18 0.38
Net Nonoperating Expense (NNE)		 2.41 2.28 0.46 0.31 0.32 0.21 0.31 0.32 0.33 0.26 0.30
Net Nonoperating Obligations (NNO)		 -12 -6.06 -4.15 -2.46 -1.68 -1.09 -0.32 -2.88 -1.94 -1.39 -0.35
Total Depreciation and Amortization (D&A)		 0.68 0.24 0.00 0.00 0.00 -0.00 0.00 0.00 0.00 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 -25,006.67% 4,860.00% 10,866.67% 21,800.00% 17,350.00% 9,720.00% -2,854.55% -3,071.43% -2,485.71% -4,200.00% 700.00%
Debt-free Net Working Capital to Revenue		 54,620.00% 126,100.00% 79,950.00% 62,850.00% 45,400.00% 20,630.00% 45.45% 38,057.14% 25,200.00% 23,500.00% 12,500.00%
Net Working Capital to Revenue		 54,620.00% 126,100.00% 79,950.00% 62,850.00% 45,400.00% 20,630.00% 45.45% 38,057.14% 25,200.00% 23,500.00% 12,500.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($6.00) ($735.00) ($1.10) ($0.71) ($0.70) ($0.46) ($0.67) ($0.63) ($0.55) ($1.00) ($0.59)
Adjusted Weighted Average Basic Shares Outstanding		 1.60M 10.66K 1.60M 1.60M 1.60M 1.60M 1.60M 1.68M 2.18M 1.95M 1.95M
Adjusted Diluted Earnings per Share		 ($6.00) ($735.00) ($1.10) ($0.71) ($0.70) ($0.46) ($0.67) ($0.63) ($0.55) ($1.00) ($0.59)
Adjusted Weighted Average Diluted Shares Outstanding		 1.60M 10.66K 1.60M 1.60M 1.60M 1.60M 1.60M 1.68M 2.18M 1.95M 1.95M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($735.00) $0.00 $0.00 $0.00 ($0.46) $0.00 $0.00 $0.00 ($1.00) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 1.60M 106.75K 1.60M 1.60M 1.60M 1.60M 1.64M 2.19M 2.23M 2.38M 24.42M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.06 -2.31 -1.22 -0.82 -0.81 -0.53 -0.76 -0.73 -0.83 -0.63 -0.71
Normalized NOPAT Margin		 0.00% -231,490.00% -121,940.00% -20,405.00% 0.00% -10,556.00% -38,220.00% 0.00% 0.00% -21,163.33% 0.00%
Pre Tax Income Margin		 0.00% -784,300.00% -168,200.00% -28,225.00% 0.00% -14,820.00% -53,650.00% 0.00% 0.00% -28,733.33% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Alaunos Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Alaunos Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Alaunos Therapeutics' net income appears to be on a downward trend, with a most recent value of -$4.18 million in 2025, falling from -$120.09 million in 2015. The previous period was -$4.68 million in 2024. Check out Alaunos Therapeutics' forecast to explore projected trends and price targets.

Alaunos Therapeutics' total operating income in 2025 was -$4.23 million, based on the following breakdown:
  • Total Gross Profit: $5 thousand
  • Total Operating Expenses: $4.23 million

Over the last 10 years, Alaunos Therapeutics' total revenue changed from $4.33 million in 2015 to $5 thousand in 2025, a change of -99.9%.

Alaunos Therapeutics' total liabilities were at $813 thousand at the end of 2025, a 17.5% increase from 2024, and a 98.8% decrease since 2015.

In the past 10 years, Alaunos Therapeutics' cash and equivalents has ranged from $1.09 million in 2024 to $140.72 million in 2015, and is currently $1.39 million as of their latest financial filing in 2025.

Over the last 10 years, Alaunos Therapeutics' book value per share changed from 0.67 in 2015 to 0.96 in 2025, a change of 44.5%.


Related Companies

Financial statements for NASDAQ:TCRT last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel